SCHEMBL2837634

SCHEMBL2837634

CC(C)(C)OC(=O)N[C@@H](c1ccc(Cl)c(Cl)c1)[C@H](O)c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A3 Q01959 2/20 0.42
S1PR3 Q99500 2/20 0.39
PTGES2 Q9H7Z7 5/20 0.37
MITF O75030 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MCL1 Q07820 3/20 0.36
BCL2 P10415 3/20 0.36
BCL2L1 Q07817 2/20 0.36
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12096647 1.00 CYP3A4 (0.42) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL2837331 1.00 CYP3A4 (0.42) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL12096650 1.00 CYP3A4 (0.42) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL2837638 1.00 CYP3A4 (0.42) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL2832215 0.89 CYP3A4 (0.46) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL2837175 0.88 CYP3A4 (0.50) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL2837632 0.84 S1PR3 (0.49) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL3808538 0.83 CYP3A4 (0.47) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL2833334 0.82 S1PR3 (0.44) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL7812854 0.79 SLC6A2 (0.47) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 CYP3A4 1043/4885CYP2D6 767/4885SLC6A2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.